Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.60 |
| ▸ | CCR3 | P51677 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 6/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | GOT1 | P17174 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5276417 | 0.85 | MAPK14 (0.61) | MAPK14CCR3MGLLHTTACHE | |
| SCHEMBL6098564 | 0.84 | HTR2A (0.43) | MAPK14HTR2AHTR2CKCNH2DRD2 | |
| SCHEMBL6096552 | 0.82 | GAA (0.57) | MAPK14CCR3MGLLGAAMAPT | |
| Hydrochloric Acid SCHEMBL27554175 | 0.81 | GAA (0.56) | MAPK14CCR3MGLLGAAMAPT | |
| SCHEMBL5280958 | 0.80 | MAPK14 (0.79) | MAPK14MGLLHTTACHEGAA | |
| SCHEMBL5274240 | 0.80 | MAPK14 (0.59) | MAPK14MAPTDRD2DRD3THRB | |
| SCHEMBL6094722 | 0.79 | MAPK14 (0.60) | MAPK14CCR3MGLLDRD2DRD3 | |
| SCHEMBL6094636 | 0.78 | MAPK14 (0.60) | MAPK14CCR3MGLLHTTACHE | |
| SCHEMBL6093813 | 0.78 | HTR2A (0.43) | GAAMAPTHTR2AHTR2CKCNH2 | |
| SCHEMBL6096879 | 0.78 | MAPK14 (0.62) | MAPK14CCR3MGLLHTTACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7084143-B2 | N-(indolecarbonyl) piperazine derivatives | MERCK PATENT GMBH (DE) | 2006-08-01 | — | — | US | claimed |
| EP-1448201-B1 | N-(INDOLCARBONYL-)PIPERAZINE DERIVATIVES FOR THE TREATMENT OF OBESITY | MERCK PATENT GMBH (DE) | 2007-11-28 | — | — | EP | disclosed |
| US-7084143-B2 | N-(indolecarbonyl) piperazine derivatives | MERCK PATENT GMBH (DE) | 2006-08-01 | — | — | US | disclosed |
| WO-2006034788-A1 | COMBINATIONS OF N-(INDOLECARBONYL-)PIPERAZINE DERIVATIVES AND SEROTONIN REUPTAKE INHIBITORS | MERCK PATENT GMBH (DE) | 2006-04-06 | — | — | WO | disclosed |
| US-20060040951-A1 | Use of 5-ht2 receptor antagonists for the treatment of sleep disorders | MERCK PATENT GMBH (DE) | 2006-02-23 | — | — | US | disclosed |
| EP-1545531-A1 | USE OF 5-HT2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SLEEP DISORDERS | MERCK PATENT GmbH (DE) | 2005-06-29 | — | — | EP | disclosed |
| US-20050014766-A1 | Use of n-(indolecarbonyl-)piperazine derivatives | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
| US-6838461-B1 | N-(indolcarbonyl-)piperazine derivatives | MERCK PATENT GMBH (DE) | 2005-01-04 | — | — | US | disclosed |
| EP-1198453-B9 | N-(INDOLCARBONYL-)PIPERAZIN DERIVATIVES | MERCK PATENT GMBH (DE) | 2004-11-10 | — | — | EP | disclosed |
| EP-1448201-A2 | USE OF N-(INDOLCARBONYL-)PIPERAZINE DERIVATIVES | MERCK PATENT GmbH (DE) | 2004-08-25 | — | — | EP | disclosed |
| WO-2004032932-A1 | USE OF 5-HT2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SLEEP DISORDERS | MERCK PATENT GMBH (DE) | 2004-04-22 | — | — | WO | disclosed |
| WO-2003045392-A2 | USE OF N-(INDOLCARBONYL-)PIPERAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2003-06-05 | — | — | WO | disclosed |
| EP-1198453-B1 | N-(INDOLCARBONYL-)PIPERAZIN DERIVATIVES | MERCK PATENT GMBH (DE) | 2003-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014766-A1 | Use of n-(indolecarbonyl-)piperazine derivatives | GPR119, CHRM1, HTR1A | MAPK14 4344/4885CCR3 3695/4885MGLL 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.